晨 会 纪 要 [2026]第 19 号 李正威 邢维洁 马丽明 汪炜 聂孟依 张弛 王雪莹 整理记录：蒋栋 研究所今日晨会要点如下: 根据 Wind 数据，上周申万一级行业医药生物下跌 0.39%，涨幅排名位列申万 31 个一级行 业第 27 位。沪深 300 指数下跌 0.62%，医药跑赢沪深 300 指数 0.23 个百分点。申万医药 生物二级子行业医疗服务 II 报收 7280.46 点，下跌 2.17%；中药 II 报收 6350.32 点，上 涨 0.89%；化学制药Ⅱ报收 13328.75 点，下跌 1.11%；生物制品Ⅱ报收 6427.70 点，上涨 0.07%；医药商业Ⅱ报收 5457.63 点，上涨 4.26%；医疗器械 II 报收 6881.47 点，上涨 0.30%。 细分板块来看，医疗服务跌幅较大。 根据Wind数据，从医疗服务板块公司的表现来看，表现居前的公司有：诺禾致源（+11.5%）、 新里程（+9.4%）、迪安诊断（+8.2%）、ST 中珠（+7.1%）、光正眼科（+6.2%）；表现 靠后的公司有：博腾股份（-6.9%）、诚达药业（-6.6%）、药明康德（-6.4%）、美迪西 ...

晨 会 纪 要 [2026]第 17 号 主 题：对近期重要经济金融新闻、行业事件、公司公告等进行点评 时 间：2026 年 1 月 27 日 8:50-9:30 会议形式：腾讯会议 参会人员：曹旭特 仇华 许雯 王攀 蒋栋 轩鹏程 文正平 张智珑 郭怡萍 李育 文 李正威 邢维洁 马丽明 汪炜 聂孟依 张弛 整理记录：李正威 研究所今日晨会要点如下: 一、金融工程 1.1、ETF 市场跟踪与配置周报（李正威） 上周 ETF 市场概况 截至 2026 年 1 月 23 日，沪深两市共有 1419 只 ETF，资产管理总规模为 57783.49 亿元。 其中股票型 ETF 共 1102 只（35709.89 亿元），债券型 ETF 共 53 只（7345.75 亿元），货币 型 ETF 共 27 只（1548.63 亿元），商品型 ETF 共 17 只（3081.67 亿元），跨境 ETF 共 208 只（10023.22 亿元），未上市 ETF 共 12 只（74.34 亿元）。 在 2026 年 1 月 19 日至 2026 年 1 月 23 日，根据 Wind 数据，按照基金上市日，本周共 有 8 只 E ...

Investment Rating - The industry investment rating is maintained at "Overweight" [3] Core Insights - The medical consumables sector saw a weekly increase of 1.72%, outperforming the CSI 300 index by 0.23 percentage points [5][10] - The current PE ratio for the medical consumables sector is 37.73X, with a PB ratio of 2.71X, indicating a slight increase in valuation metrics compared to the previous week [6][18][20] Industry Performance - Over the past month, the medical consumables sector has shown a relative return of 9%, while the absolute return over the last 12 months is 22% [4] - The sector's performance is compared to other sub-sectors, with notable fluctuations in the medical and pharmaceutical industries [12] Industry Dynamics and Key Announcements - The 2026 National Health System Grassroots Health and Financial Work Conference emphasized the importance of strengthening basic medical services and expanding rehabilitation and nursing services, which is expected to drive demand for consumables [7][21] - The focus on grassroots healthcare institutions is anticipated to enhance the demand for consumables related to common and chronic diseases, as well as rehabilitation equipment [21] Investment Recommendations - The report suggests focusing on leading companies with strong cost control and innovation capabilities, particularly in the context of ongoing procurement normalization [8][23] - Companies with a diverse product line and strong market presence in high-value consumables, such as HuiTai Medical and MaiPu Medical, are highlighted as potential investment opportunities [8][23]

Investment Rating - The report maintains an "Overweight" rating for the in vitro diagnostics industry [4][54]. Core Views - The in vitro diagnostics industry is stabilizing due to policy and technological advancements, including the accelerated integration of AI in diagnostics, the implementation of price reforms, and the stabilization of centralized procurement impacts [4][54]. - The report highlights the importance of focusing on specific growth areas within the industry, such as chemiluminescence in immunodiagnostics and PCR in molecular diagnostics, with companies like YHLO and Shengxiang Bio being recommended for attention [4][54]. Summary by Sections Industry Performance - The pharmaceutical and biological sector decreased by 0.39%, while the in vitro diagnostics sector increased by 0.42% during the week [1][20]. - The in vitro diagnostics sector's PE ratio is currently at 40.90X, with a recent increase of 0.17X, and the PB ratio is at 1.87X, up by 0.01X from the previous week [3][30]. Key Developments - AI diagnostics are evolving from auxiliary tools to core components of clinical processes, enhancing diagnostic efficiency and driving industry modernization [4][54]. - The Chongqing Medical Insurance Bureau has introduced a price reform draft for pathological services, which is expected to enhance the value recognition of diagnostic services [4][54]. - The impact of centralized procurement is stabilizing, with price pressures gradually easing and testing volumes expected to stabilize following the unbundling of service packages [4][54]. Company Performance - Notable companies in the medical services sector include Aotai Bio (+7.9%), Saikexide (+4.5%), and Mingde Bio (+4.0%), while underperformers include Rejing Bio (-8.7%) and Botuo Bio (-3.3%) [2][25]. - The report suggests that the domestic biochemical diagnostics sector has largely overcome foreign constraints, indicating a completed localization process [4][54].

Investment Rating - The industry maintains an "Overweight" rating [9] Core Views - The report highlights the performance of the traditional Chinese medicine (TCM) sector, noting a 0.89% increase in the TCM II index, making it the second-best performing sub-sector in the pharmaceutical industry [3] - The report emphasizes the importance of the 2025 performance outlook and the progress of the essential drug catalog adjustments, with many companies showing positive profit growth [6] - The report suggests that the TCM industry may continue to experience structural differentiation, with companies focusing on external markets and innovation to find new growth points [6] Market Performance - The TCM II index closed at 6406.83 points, up 0.89% for the week, while the overall pharmaceutical index fell by 0.39% [3] - The best-performing companies in the TCM sector included *ST Changyao, ST Xiangxue, and Fangsheng Pharmaceutical, while the worst performers included Zhenbaodao and Pianzaihuang [3] Valuation - The TCM sector's PE (ttm) was 27.34X, up 0.23X week-on-week, with a PB (lf) of 2.3X, also showing a slight increase [4] - The PE is at the 28.89% percentile since 2013, while the PB is at the 5.74% percentile [4] Raw Material Market - The TCM raw material index rose by 1.1% due to increased demand for tonic herbs and price hikes in certain materials [5] - The overall market for TCM materials remains volatile, with a notable increase in demand for tonic herbs [5] Investment Suggestions - The report recommends focusing on three main investment themes: price governance, consumption recovery, and state-owned enterprise reform [7] - Specific investment targets include companies with strong R&D capabilities, those less affected by centralized procurement, and brands with strong market presence [13]

Investment Rating - The industry investment rating is maintained at "Overweight" [3][39] Core Views - The rare earth magnetic materials industry outperformed the market, with a price increase of 1.66% this week, surpassing the benchmark (CSI 300) by 2.28 percentage points [5][12] - The industry valuation (TTM P/E) has rebounded to 83.53x, currently at the 92.1% historical percentile [5][12] - Short-term adjustments are expected after a significant price increase in the industry chain, but medium to long-term demand remains stable [39] Summary by Sections Market Performance - The rare earth magnetic materials industry saw a relative return of 14% over one month, 5% over three months, and 74% over twelve months, with absolute returns of 16%, 7%, and 98% respectively [4] - The industry valuation has increased by 1.37x this week [5] Price Trends - Domestic light rare earth concentrate prices remained stable, while medium and heavy rare earth prices declined [6][9] - Prices for praseodymium and neodymium showed weak fluctuations, with praseodymium oxide prices decreasing by 0.37% [9][14] - Dysprosium and terbium prices were adjusted downwards due to insufficient downstream demand [9][18] Fundamental Changes - Supply-side growth is limited, with tight spot circulation and a positive long-term demand outlook [9][38] - The demand from downstream sectors, such as new energy vehicles, is experiencing marginal declines, while industrial trends remain generally positive [9][38] Valuation Perspective - Current absolute and relative historical valuation levels are supported by loose liquidity and favorable industrial policies [9][38] - The industry is expected to enter a phase of stable fluctuations in valuation due to regulatory constraints [39] Investment Recommendations - The report suggests maintaining an "Overweight" rating, focusing on upstream rare earth resource companies and downstream magnetic material companies with strong customer structures and growth potential [39][42]

证券研究报告 2026 年 01 月 25 日 湘财证券研究所 根据 Wind 数据，本周申万一级行业医药生物下跌 0.39%，涨幅排名位列申 万 31 个一级行业第 27 位。沪深 300 指数下跌 0.62%，医药跑赢沪深 300 指数 0.23 个百分点。申万医药生物二级子行业医疗服务 II 报收 7280.46 点，下跌 2.17%；中药 II 报收 6350.32 点，上涨 0.89%；化学制药Ⅱ报收 13328.75 点，下跌 1.11%；生物制品Ⅱ报收 6427.70 点，上涨 0.07%；医 药商业Ⅱ报收 5457.63 点，上涨 4.26%；医疗器械 II 报收 6881.47 点，上 涨 0.30%。细分板块来看，医疗服务跌幅较大。 根据 Wind 数据，从医疗服务板块公司的表现来看，表现居前的公司有： 诺禾致源（+11.5%）、新里程（+9.4%）、迪安诊断（+8.2%）、ST 中珠（+7.1%）、 光正眼科（+6.2%）；表现靠后的公司有：博腾股份（-6.9%）、诚达药业 （-6.6%）、药明康德（-6.4%）、美迪西（-4.8%）、成都先导（-4.5%）。从 个股涨跌幅来看 CXO ...

Investment Rating - The industry rating is maintained at "Overweight" [7][35] Core Insights - The regulatory environment is expected to strengthen, focusing on substantial risks and enhancing regulatory efficiency through classification and grading methods. The application of regulatory technology, including big data and artificial intelligence, will significantly deepen [7][33] - The banking sector's transformation path is becoming clearer, with a focus on reducing and improving small and medium financial institutions, promoting differentiated competition, and aligning resources with key economic development areas [7][33] Summary by Sections Regulatory Developments - The National Financial Supervision Administration held a meeting emphasizing the importance of risk management and the progress made in reforming small and medium financial institutions in 2025. The meeting also highlighted the expansion and efficiency of urban real estate financing coordination mechanisms [6][31] - In 2026, efforts to resolve risks will continue, with a clear mandate to avoid "explosive" failures in the financial sector. The meeting proposed ongoing reforms for small and medium financial institutions and a focus on long-term mechanisms for risk management [7][33] Market Performance - The banking index fell by 2.70% during the period from January 19 to January 25, 2026, underperforming the CSI 300 index by 2.08 percentage points. The performance of large banks, joint-stock banks, city commercial banks, and rural commercial banks varied, with regional banks showing relatively better performance [11] Investment Recommendations - As risks in key areas gradually resolve, there is potential for valuation recovery in the banking sector. The stability of interest margins is expected to improve, and performance is showing signs of stabilization. In a low-interest-rate environment, the high dividend yield of bank stocks is highlighted as a key investment value. Recommendations include focusing on state-owned banks with stable asset deployment and joint-stock and regional banks with growth potential, such as Industrial and Commercial Bank of China, Bank of China, and others [9][35]

Investment Rating - The industry maintains a "Buy" rating [8] Core Insights - The real estate market is entering a traditional off-season, with expectations for increased policy support [5] - In major cities, the transaction volume for new homes has seen a significant decline compared to second-hand homes, indicating weaker demand [4] - The market anticipates that other first-tier cities will follow Beijing's lead in optimizing purchase restrictions after observing declining transaction data [5] Summary by Sections Core Cities - Beijing: Second-hand home daily transactions averaged 558 units (up 16.3% year-on-year), while new home transactions averaged 80 units (down 45% year-on-year) [2] - Shanghai: Second-hand home daily transactions averaged 609 units (up 10% year-on-year), with new home transactions remaining flat [2] - Shenzhen: Second-hand home daily transactions averaged 201 units (up 68% year-on-year), while new home transactions dropped 57% [3] National Key Cities - New home transaction volume in 30 major cities decreased by 38% year-on-year, while second-hand home transactions increased by 9.2% year-on-year, primarily due to a low base effect from the previous year [4] Investment Recommendations - The report suggests focusing on leading real estate companies with land reserves in core cities and high-end improvement products, such as Poly Developments [5] - It also highlights the potential for valuation recovery in leading intermediary firms as the proportion of second-hand home transactions continues to rise, citing companies like I Love My Home [5]

Investment Rating - The industry investment rating is maintained at "Overweight" [2][8]. Core Insights - The vaccine industry is undergoing a transformation from scale expansion to innovation-driven growth, facing short-term pain due to supply-demand imbalance and homogenized competition, but the long-term growth logic remains intact, driven by policy, demand, and technology [8][25]. - Recent developments in vaccine research and international expansion signal positive trends, with a shift in focus from child vaccination to a broader lifecycle approach due to demographic changes [3][7]. Summary by Sections Industry Performance - The vaccine sector has seen a relative performance decline of 25% over the past 12 months compared to the CSI 300 index, with absolute returns down by 2% [3]. - The vaccine index rose by 0.49% in the last week, while the overall pharmaceutical sector declined by 0.39% [4][5]. Company Developments - Huashan Vaccine received approval for clinical trials of its recombinant shingles vaccine [3]. - Kanghua Bio announced a projected net profit decline of 41.55%-52.09% for 2025, primarily due to decreased vaccine sales and market competition [3]. - Kexing Bio secured a two-year exclusive order for hepatitis A vaccine in Oman, marking a significant breakthrough in the Middle East market [3]. - Aimee Vaccine's 20-valent pneumococcal polysaccharide conjugate vaccine has been approved for clinical trials [3]. Market Dynamics - The industry is experiencing a shift in demand dynamics, with a notable decrease in newborn population affecting vaccine demand negatively, necessitating a re-evaluation of growth strategies [3][7]. - The vaccine sector's price competition is intensifying due to a high proportion of Me-too products, leading to significant price drops for some vaccines [7][22]. Valuation Metrics - The vaccine sector's PE (ttm) stands at 93.89X, with a PB (lf) of 1.82X, indicating a slight increase in valuation metrics compared to previous periods [6][18]. Investment Recommendations - The report suggests focusing on companies with strong innovation capabilities and differentiated product lines, particularly those with high technical barriers and international market strategies [8][25]. - Long-term investment opportunities are seen in companies that can leverage innovation and international expansion to navigate current market challenges [7][8].